{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T13:03:47Z","timestamp":1774789427226,"version":"3.50.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001249","name":"University of Tasmania","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001249","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40273-025-01486-z","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T10:06:45Z","timestamp":1746612405000},"page":"969-985","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Societal Versus Healthcare Perspectives on the Cost Effectiveness of Ocrelizumab for Treatment of Primary Progressive Multiple Sclerosis in Aotearoa New Zealand"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9410-1667","authenticated-orcid":false,"given":"Richard J.","family":"Milne","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0167-9444","authenticated-orcid":false,"given":"Carsten","family":"Schousboe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1820-6758","authenticated-orcid":false,"given":"Julie A.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5638-8786","authenticated-orcid":false,"given":"John","family":"Mottershead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"issue":"14","key":"1486_CR1","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS. Mult Scler J. 2020;26(14):1816\u201321. https:\/\/doi.org\/10.1177\/1352458520970841.","journal-title":"Mult Scler J"},{"key":"1486_CR2","unstructured":"King R. Atlas of MS 2020 [updated September, 2023. 3. https:\/\/www.msif.org\/resource\/atlas-of-ms-2020."},{"issue":"1","key":"1486_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004073","volume":"4","author":"J Palace","year":"2014","unstructured":"Palace J, Bregenzer T, Tremlett H, Oger J, Zhu F, Boggild M, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ-Open. 2014;4(1): e004073. https:\/\/doi.org\/10.1136\/bmjopen-2013-004073.","journal-title":"BMJ-Open."},{"issue":"4","key":"1486_CR4","doi-asserted-by":"publisher","first-page":"180","DOI":"10.5694\/mja2.51645","volume":"217","author":"BV Taylor","year":"2022","unstructured":"Taylor BV. What causes multiple sclerosis? Getting closer to the answers. Med J Aust. 2022;217(4):180\u20132. https:\/\/doi.org\/10.5694\/mja2.51645.","journal-title":"Med J Aust"},{"key":"1486_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jocn.2015.09.020","volume":"28","author":"S Alla","year":"2016","unstructured":"Alla S, Pearson JF, Taylor BV, Miller DH, Clarke G, Richardson A, et al. Disability profile of multiple sclerosis in New Zealand. J Clin Neurosci. 2016;28:97\u2013101. https:\/\/doi.org\/10.1016\/j.jocn.2015.09.020.","journal-title":"J Clin Neurosci"},{"issue":"1","key":"1486_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2377-12-49","volume":"12","author":"AI Spooren","year":"2012","unstructured":"Spooren AI, Timmermans AA, Seelen HA. Motor training programs of arm and hand in patients with MS according to different levels of the ICF: a systematic review. BMC Neurol. 2012;12(1):1\u201311. https:\/\/doi.org\/10.1186\/1471-2377-12-49.","journal-title":"BMC Neurol"},{"issue":"7","key":"1486_CR7","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1136\/jnnp-2022-330582","volume":"94","author":"R Leadbetter","year":"2023","unstructured":"Leadbetter R, MacCaskill M, Myall D, Taylor B, Joshi P, Mason D. Multiple sclerosis mortality in New Zealand: a nationwide prospective study. J Neurol Neurosurg Psychiatry. 2023;94(7):511\u20137. https:\/\/doi.org\/10.1136\/jnnp-2022-330582.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1486_CR8","unstructured":"Bealing M, Krieble T, Spring S. Multiple sclerosis: assessing the social and economic burden. Wellington: NZ Institute of Economic Research; 2020. https:\/\/www.nzier.org.nz\/publications. Accessed 31 Mar 2025."},{"issue":"5","key":"1486_CR9","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/1352458515605909","volume":"22","author":"S Alla","year":"2016","unstructured":"Alla S, Pearson JF, Taylor BV, Roxburgh R, Clarke G, Miller DH, et al. An investigation of the relationship between latitude and multiple sclerosis severity in New Zealand. Mult Scler. 2016;22(5):705\u20137. https:\/\/doi.org\/10.1177\/1352458515605909.","journal-title":"Mult Scler"},{"issue":"11","key":"1486_CR10","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1177\/1352458519861270","volume":"26","author":"JA Campbell","year":"2020","unstructured":"Campbell JA, Simpson S Jr, Ahmad H, Taylor BV, van der Mei I, Palmer AJ. Change in multiple sclerosis prevalence over time in Australia 2010\u20132017 utilising disease-modifying therapy prescription data. Mult Scler J. 2020;26(11):1315\u201328. https:\/\/doi.org\/10.1177\/1352458519861270.","journal-title":"Mult Scler J"},{"issue":"3","key":"1486_CR11","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/ane.12714","volume":"136","author":"JF Pearson","year":"2017","unstructured":"Pearson JF, Alla S, Clarke G, Mason DF, Anderson T, Richardson A, et al. Multiple sclerosis impact on employment and income in New Zealand. Acta Neurol Scand. 2017;136(3):223\u201332. https:\/\/doi.org\/10.1111\/ane.12714.","journal-title":"Acta Neurol Scand"},{"issue":"10","key":"1486_CR12","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1136\/jnnp.2006.104216","volume":"78","author":"N Figved","year":"2007","unstructured":"Figved N, Myhr K-M, Larsen J-P, Aarsland D. Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms. J Neurol Neurosurg Psychiatry. 2007;78(10):1097\u2013102. https:\/\/doi.org\/10.1136\/jnnp.2006.104216.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1486_CR13","doi-asserted-by":"publisher","first-page":"117405","DOI":"10.1016\/j.socscimed.2024.117405","volume":"363","author":"T Adal","year":"2024","unstructured":"Adal T, van der Mei I, Taylor B, de Graaff B, Palmer A, Chen G, et al. Investigation of the health economic analysis of informal care for people living with a chronic neurological disease: a systematic review and meta-analysis of the global evidence for multiple sclerosis. Soc Sci Med. 2024;363:117405. https:\/\/doi.org\/10.1016\/j.socscimed.2024.117405.","journal-title":"Soc Sci Med"},{"key":"1486_CR14","doi-asserted-by":"publisher","first-page":"5463451","DOI":"10.1155\/2020\/5463451","volume":"2020","author":"K Daniels","year":"2020","unstructured":"Daniels K, van der Nat PB, Frequin STFM, van der Wees PJ, Biesma DH, Hoogervorst ELJ, et al. Real-world results of ocrelizumab treatment for primary progressive multiple sclerosis. Mult Scler Int. 2020;2020:5463451. https:\/\/doi.org\/10.1155\/2020\/5463451.","journal-title":"Mult Scler Int"},{"issue":"3","key":"1486_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1606468","volume":"376","author":"X Montalban","year":"2017","unstructured":"Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1606468.","journal-title":"N Engl J Med"},{"issue":"6","key":"1486_CR16","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1007\/s13311-023-01415-y","volume":"20","author":"CG Chisari","year":"2023","unstructured":"Chisari CG, Bianco A, Brescia Morra V, Calabrese M, Capone F, Cavalla P, et al. Effectiveness of ocrelizumab in primary progressive multiple sclerosis: a multicenter, retrospective, real-world study (OPPORTUNITY). Neurother. 2023;20(6):1696\u2013706. https:\/\/doi.org\/10.1007\/s13311-023-01415-y.","journal-title":"Neurother"},{"issue":"6","key":"1486_CR17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40273-020-00889-4","volume":"38","author":"P Auguste","year":"2020","unstructured":"Auguste P, Colquitt J, Connock M, Loveman E, Court R, Ciccarelli O, et al. Ocrelizumab for treating patients with primary progressive multiple sclerosis: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2020;38(6):527\u201336. https:\/\/doi.org\/10.1007\/s40273-020-00889-4.","journal-title":"Pharmacoeconomics"},{"key":"1486_CR18","unstructured":"Federal Drug Authority USA. FDA approves new drug to treat multiple sclerosis. 2017. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-new-drug-treat-multiple-sclerosis. Accessed 31 Mar 2025."},{"key":"1486_CR19","unstructured":"NICE. Ocrelizumab for treating primary progressive multiple sclerosis. Technology appraisal guidance. Reference number:TA585. 2019. https:\/\/www.nice.org.uk\/guidance\/ta585\/evidence\/. Accessed 31 Mar 2025."},{"key":"1486_CR20","unstructured":"Anonymous. Ocrevus: ocrelizumab. European Medicines Agency; 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ocrevus. Accessed 31 Mar 2025."},{"key":"1486_CR21","unstructured":"Anonymous. Pharmac funds first treatment for primary progressive multiple sclerosis. New Zealand Pharmaceutical Management Agency; 2023. https:\/\/pharmac.govt.nz\/news-and-resources\/news\/2023-09-04-media-release-pharmac-funds-first-treatment-for-primary-progressive-multiple-sclerosis."},{"key":"1486_CR22","doi-asserted-by":"publisher","DOI":"10.4324\/9781351029780","volume-title":"Cost-benefit analysis","author":"EJ Mishan","year":"2020","unstructured":"Mishan EJ, Quah E. Cost-benefit analysis. Milton Park: Routledge; 2020."},{"issue":"2","key":"1486_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40273-022-01221-y","volume":"41","author":"TS Av\u015far","year":"2023","unstructured":"Av\u015far TS, Yang X, Lorgelly P. How is the societal perspective defined in health technology assessment? Guidelines from around the globe. Pharmacoeconomics. 2023;41(2):123\u201338. https:\/\/doi.org\/10.1007\/s40273-022-01221-y.","journal-title":"Pharmacoeconomics"},{"key":"1486_CR24","unstructured":"Pharmac. Prescription for pharmacoeconomic analysis: methods for cost-utility analysis. New Zealand Pharmaceutical Management Agency; 2020. https:\/\/pharmac.govt.nz\/medicine-funding-and-supply\/the-funding-process\/policies-manuals-and-processes\/economic-analysis\/prescription-for-pharmacoeconomic-analysis-methods-for-cost-utility-analysis. Accessed 31 Mar 2025."},{"key":"1486_CR25","doi-asserted-by":"publisher","unstructured":"Zhao Y, Feng H-m, Qu J, Luo X, Ma W-j, Tian J-h. A systematic review of pharmacoeconomic guidelines. Journal of medical economics. 2018;21(1):85\u201396. https:\/\/doi.org\/10.1080\/13696998.2017.1387118","DOI":"10.1080\/13696998.2017.1387118"},{"issue":"10","key":"1486_CR26","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316(10):1093\u2013103. https:\/\/doi.org\/10.1001\/jama.2016.12195.","journal-title":"JAMA"},{"key":"1486_CR27","unstructured":"Pharmac. Ocrelizumab: New Zealand Pharmaceutical Management Agency; 2023. https:\/\/schedule.pharmac.govt.nz\/2024\/06\/01\/SA2273.pdf. Accessed 31 Mar 2025."},{"key":"1486_CR28","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"AH Briggs","year":"2006","unstructured":"Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006."},{"key":"1486_CR29","unstructured":"Anonymous. Discount rates and CPI assumptions for accounting valuation purposes: NZ Treasury; 2025. https:\/\/www.treasury.govt.nz\/information-and-services\/public-sector-leadership\/guidance\/reporting-financial\/discount-rates\/discount-rates-and-cpi-assumptions-accounting-valuation-purposes. Accessed 31 Mar 2025."},{"key":"1486_CR30","doi-asserted-by":"publisher","unstructured":"Butzkueven H, Chapman J, Cristiano E, Grand\u2019Maison F, Hoffmann M, Izquierdo G, et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler J. 2006;12(6):769\u201374. https:\/\/doi.org\/10.1177\/1352458506070775","DOI":"10.1177\/1352458506070775"},{"key":"1486_CR31","unstructured":"NICE. Single Technology Appraisal: Ocrelizumab for treating primary progressive multiple sclerosis [ID938]: committee papers. 2018. https:\/\/www.nice.org.uk\/guidance\/ta585\/evidence\/appraisal-consultation-committee-papers-pdf-6786071101. Accessed 31 Mar 2025."},{"key":"1486_CR32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.msard.2018.08.001","volume":"25","author":"K Harding","year":"2018","unstructured":"Harding K, Anderson V, Williams O, Willis M, Butterworth S, Tallantyre E, et al. A contemporary study of mortality in the multiple sclerosis population of south east Wales. Mult Scler Relat Disord. 2018;25:186\u201391. https:\/\/doi.org\/10.1016\/j.msard.2018.08.001.","journal-title":"Mult Scler Relat Disord."},{"key":"1486_CR33","unstructured":"Ahmad H, Palmer A, Campbell J, van der Mei I, Taylor B. Health economic impact of multiple sclerosis in Australia in 2017. An analysis of MS Research Australia\u2019s platform \u2013 the Australian MS Longitudinal Study (AMSLS) Tasmania, Australia: Menzies Institute for Medical Research, University of Tasmania; 2018. https:\/\/www.msaustralia.org.au\/wp-content\/uploads\/2018\/08\/executive-summary_health-economic-impact-of-ms-in-australia-in-2017-report_ms-research-australia.pdf."},{"key":"1486_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103138","volume":"54","author":"H Ahmad","year":"2021","unstructured":"Ahmad H, van der Mei I, Taylor B, Zhao T, Xia Q, Palmer AJ. Does health-related quality of life differ between people with relapse onset and progressive onset Multiple Sclerosis? Mult Scler Relat Disord. 2021;54: 103138. https:\/\/doi.org\/10.1016\/j.msard.2021.103138.","journal-title":"Mult Scler Relat Disord."},{"issue":"2","key":"1486_CR35","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1007\/s11136-022-03214-y","volume":"32","author":"JA Campbell","year":"2023","unstructured":"Campbell JA, Ahmad H, Chen G, van der Mei I, Taylor BV, Claflin S, et al. Validation of the EQ-5D-5L and psychosocial bolt-ons in a large cohort of people living with multiple sclerosis in Australia. Qual Life Res. 2023;32(2):553\u201368. https:\/\/doi.org\/10.1007\/s11136-022-03214-y.","journal-title":"Qual Life Res"},{"issue":"6","key":"1486_CR36","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s10198-022-01518-x","volume":"24","author":"S Claflin","year":"2023","unstructured":"Claflin S, Campbell JA, Norman R, Mason DF, Kalincik T, Simpson-Yap S, et al. Using the EQ-5D-5L to investigate quality-of-life impacts of disease-modifying therapy policies for people with multiple sclerosis (MS) in New Zealand. Eur J Health Econ. 2023;24(6):939\u201350. https:\/\/doi.org\/10.1007\/s10198-022-01518-x.","journal-title":"Eur J Health Econ"},{"key":"1486_CR37","doi-asserted-by":"publisher","unstructured":"Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J, Group MS, et al. New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler J. 2017;23(8):1123\u201336; https:\/\/doi.org\/10.1177\/1352458517694432.","DOI":"10.1177\/1352458517694432"},{"key":"1486_CR38","doi-asserted-by":"publisher","unstructured":"Thompson A, Kobelt G, Berg J, Capsa D, Eriksson J, Miller D, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for the United Kingdom. Mult Scler. 2017;23(2_suppl):204\u201316; https:\/\/doi.org\/10.1177\/1352458517708687.","DOI":"10.1177\/1352458517708687"},{"key":"1486_CR39","unstructured":"Anonymous. Consumers Price Index: Statistics New Zealand; 2025. https:\/\/www.stats.govt.nz\/information-releases\/consumers-price-index-march-2024-quarter\/. Accessed 31 Mar 2025."},{"key":"1486_CR40","unstructured":"Pharmac. Cost Resource Manual 2018. https:\/\/pharmac.govt.nz\/medicine-funding-and-supply\/the-funding-process\/policies-manuals-and-processes\/economic-analysis\/cost-resource-manual. Accessed 31 Mar 2025."},{"key":"1486_CR41","unstructured":"Roche Hl. Safety of ocrelizumab in multiple sclerosis: Up to 11 years of updated analysis in patients with relapsing and progressive multiple sclerosis 2024. https:\/\/www.ocrelizumabinfo.global\/en\/homepage\/updated-safety-analysis.html. Accessed 31 Mar 2025."},{"key":"1486_CR42","doi-asserted-by":"crossref","unstructured":"Brent R. Cost-benefit analysis versus cost-effectiveness analysis from a societal perspective in healthcare. Int J Environ Res Public Health. 2023;20(5):4637. https:\/\/www.mdpi.com\/1660-4601\/20\/5\/4637.","DOI":"10.3390\/ijerph20054637"},{"key":"1486_CR43","unstructured":"Treasury N. cBAX spreadsheet model: NZ Treasury; 2023. https:\/\/www.treasury.govt.nz\/sites\/default\/files\/2023-12\/cbax-model-dec2023.xlsx. Accessed 31 Mar 2025."},{"key":"1486_CR44","unstructured":"Treasury N. The Treasury's CBAx Tool. 2024. https:\/\/www.treasury.govt.nz\/information-and-services\/state-sector-leadership\/investment-management\/plan-investment-choices\/cost-benefit-analysis-including-public-sector-discount-rates\/treasurys-cbax-tool. Accessed 31 Mar 2025."},{"issue":"6","key":"1486_CR45","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40273-021-01112-8","volume":"40","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: updated reporting guidance for health economic evaluations. Pharmacoeconomics. 2022;40(6):601\u20139. https:\/\/doi.org\/10.1007\/s40273-021-01112-8.","journal-title":"Pharmacoeconomics"},{"key":"1486_CR46","unstructured":"NICE. NICE health technology evaluations: the manual 2023. https:\/\/www.nice.org.uk\/process\/pmg36\/resources\/nice-health-technology-evaluations-the-manual-pdf-72286779244741. Accessed 31 Mar 2025."},{"issue":"1350","key":"1486_CR47","first-page":"99","volume":"125","author":"S Metcalfe","year":"2012","unstructured":"Metcalfe S, Rodgers A, Werner R, Schousboe C. PHARMAC has no cost-effectiveness threshold. N Z Med J. 2012;125(1350):99\u2013101.","journal-title":"N Z Med J"},{"key":"1486_CR48","doi-asserted-by":"crossref","unstructured":"Alsop P, Crausaz S. Implementing social investment: Pharmac\u2019s experience. In: Boston J, Gills D, editors. Social Investment: a New Zealand policy experiment. Wellington: Bridget Wlliams Books; 2017.","DOI":"10.7810\/9781988533582_11"},{"key":"1486_CR49","unstructured":"York University, UK. Net Monetary Benefit. https:\/\/yhec.co.uk\/glossary\/net-monetary-benefit\/. Accessed 31 Mar 2025."},{"key":"1486_CR50","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s11136-005-0891-6","volume":"15","author":"A Miller","year":"2006","unstructured":"Miller A, Dishon S. Health-related quality of life in multiple sclerosis: the impact of disability, gender and employment status. Qual Life Res. 2006;15:259\u201371. https:\/\/doi.org\/10.1007\/s11136-005-0891-6.","journal-title":"Qual Life Res"},{"issue":"10","key":"1486_CR51","doi-asserted-by":"publisher","first-page":"5382","DOI":"10.1007\/s00415-022-11193-w","volume":"269","author":"M Filippi","year":"2022","unstructured":"Filippi M, Amato MP, Centonze D, Gallo P, Gasperini C, Inglese M, et al. Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion. J Neurol. 2022;269(10):5382\u201394. https:\/\/doi.org\/10.1007\/s00415-022-11193-w.","journal-title":"J Neurol"},{"key":"1486_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2021.693017","volume":"12","author":"CS Simonsen","year":"2021","unstructured":"Simonsen CS, Flemmen H\u00d8, Broch L, Brunborg C, Berg-Hansen P, Moen SM, et al. Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry. Front Neurol. 2021;12:1\u201313. https:\/\/doi.org\/10.3389\/fneur.2021.693017.","journal-title":"Front Neurol"},{"issue":"2","key":"1486_CR53","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jval.2018.08.011","volume":"22","author":"V Chirikov","year":"2019","unstructured":"Chirikov V, Ma I, Joshi N, Patel D, Smith A, Giambrone C, et al. Cost-Effectiveness of alemtuzumab in the treatment of relapsing forms of multiple sclerosis in the United States. Value Health. 2019;22(2):168\u201376. https:\/\/doi.org\/10.1016\/j.jval.2018.08.011.","journal-title":"Value Health."},{"issue":"10","key":"1486_CR54","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/13696998.2017.1357564","volume":"20","author":"MA Frasco","year":"2017","unstructured":"Frasco MA, Shih T, Incerti D, Diaz Espinosa O, Vania DK, Thomas N. Incremental net monetary benefit of ocrelizumab relative to subcutaneous interferon beta-1a. J Med Econ. 2017;20(10):1074\u201382. https:\/\/doi.org\/10.1080\/13696998.2017.1357564.","journal-title":"J Med Econ"},{"issue":"1","key":"1486_CR55","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1080\/13696998.2022.2078103","volume":"25","author":"S Montgomery","year":"2022","unstructured":"Montgomery S, Woodhouse F, Vudumula U, Gudala K, Duddy M, Kroes M. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK. J Med Econ. 2022;25(1):669\u201378. https:\/\/doi.org\/10.1080\/13696998.2022.2078103.","journal-title":"J Med Econ"},{"issue":"6","key":"1486_CR56","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s41669-022-00363-1","volume":"6","author":"M Baharnoori","year":"2022","unstructured":"Baharnoori M, Bhan V, Clift F, Thomas K, Mouallif S, Adlard N, et al. Cost-effectiveness analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. PharmacoEconomics-Open. 2022;6(6):859\u201370. https:\/\/doi.org\/10.1007\/s41669-022-00363-1.","journal-title":"PharmacoEconomics-Open."},{"issue":"3","key":"1486_CR57","doi-asserted-by":"publisher","first-page":"154","DOI":"10.18502\/cjn.v20i3.7691","volume":"20","author":"N Ayati","year":"2021","unstructured":"Ayati N, Taheri S, Sahraian MA, Nikfar S. Cost-effectiveness of ocrelizumab for treatment of Iranian patients with relapsing multiple sclerosis. Curr J Neurol. 2021;20(3):154\u201361. https:\/\/doi.org\/10.18502\/cjn.v20i3.7691.","journal-title":"Curr J Neurol."},{"key":"1486_CR58","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.vhri.2023.02.008","volume":"36","author":"CE Navarro","year":"2023","unstructured":"Navarro CE, Betancur JE. Cost-utility analysis comparing ocrelizumab versus rituximab in the treatment of relapsing-remitting multiple sclerosis: the colombian perspective. Value Health Reg Issues. 2023;36:83\u201391. https:\/\/doi.org\/10.1016\/j.vhri.2023.02.008.","journal-title":"Value Health Reg Issues."},{"issue":"2","key":"1486_CR59","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s41669-022-00381-z","volume":"7","author":"P Martins","year":"2023","unstructured":"Martins P, Vandewalle B, Felix J, Capela CM, Cerqueira JJ, Salgado AV, et al. Cost-effectiveness analysis of ocrelizumab for the treatment of relapsing and primary progressive multiple sclerosis in Portugal. Pharmacoeconom Open. 2023;7(2):229\u201341. https:\/\/doi.org\/10.1007\/s41669-022-00381-z.","journal-title":"Pharmacoeconom Open."},{"issue":"12","key":"1486_CR60","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s40263-018-0566-9","volume":"32","author":"M Zimmermann","year":"2018","unstructured":"Zimmermann M, Brouwer E, Tice JA, Seidner M, Loos AM, Liu S, et al. Disease-modifying therapies for relapsing-remitting and primary progressive multiple sclerosis: a cost-utility analysis. CNS Drugs. 2018;32(12):1145\u201357. https:\/\/doi.org\/10.1007\/s40263-018-0566-9.","journal-title":"CNS Drugs"},{"issue":"12","key":"1486_CR61","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2471\/BLT.15.164418","volume":"94","author":"MY Bertram","year":"2016","unstructured":"Bertram MY, Lauer JA, De Joncheere K, Edejer T, Hutubessy R, Kieny M-P, et al. Cost-effectiveness thresholds: pros and cons. Bull World Health Org. 2016;94(12):925. https:\/\/doi.org\/10.2471\/BLT.15.164418.","journal-title":"Bull World Health Org"},{"issue":"6","key":"1486_CR62","doi-asserted-by":"publisher","first-page":"e833","DOI":"10.1016\/S2214-109X(23)00162-6","volume":"11","author":"A Pichon-Riviere","year":"2023","unstructured":"Pichon-Riviere A, Drummond M, Palacios A, Garcia-Marti S, Augustovski F. Determining the efficiency path to universal health coverage: cost-effectiveness thresholds for 174 countries based on growth in life expectancy and health expenditures. Lancet Glob Health. 2023;11(6):e833\u201342. https:\/\/doi.org\/10.1016\/S2214-109X(23)00162-6.","journal-title":"Lancet Glob Health"},{"issue":"4","key":"1486_CR63","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jval.2022.01.010","volume":"25","author":"PJ Neumann","year":"2022","unstructured":"Neumann PJ, Garrison LP, Willke RJ. The history and future of the \u201cISPOR Value Flower\u201d: addressing limitations of conventional cost-effectiveness analysis. Value Health. 2022;25(4):558\u201365. https:\/\/doi.org\/10.1016\/j.jval.2022.01.010.","journal-title":"Value Health."},{"issue":"2","key":"1486_CR64","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","volume":"21","author":"DN Lakdawalla","year":"2018","unstructured":"Lakdawalla DN, Doshi JA, Garrison LP Jr, Phelps CE, Basu A, Danzon PM. Defining elements of value in health care\u2014a health economics approach: an ISPOR Special Task Force report [3]. Value Health. 2018;21(2):131\u20139. https:\/\/doi.org\/10.1016\/j.jval.2017.12.007.","journal-title":"Value Health."},{"issue":"5","key":"1486_CR65","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1212\/WNL.42.5.991","volume":"42","author":"A Sadovnick","year":"1992","unstructured":"Sadovnick A, Ebers G, Wilson R, Paty D. Life expectancy in patients attending multiple sclerosis clinics. Neurology. 1992;42(5):991\u20134.","journal-title":"Neurology"},{"issue":"4","key":"1486_CR66","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.jval.2016.01.002","volume":"19","author":"A Hawton","year":"2016","unstructured":"Hawton A, Green C. Health utilities for multiple sclerosis. Value Health. 2016;19(4):460\u20138. https:\/\/doi.org\/10.1016\/j.jval.2016.01.002.","journal-title":"Value Health."},{"key":"1486_CR67","unstructured":"Anonymous. The state of caring in Aotearoa. A report for Carers NZ and the Carers Alliance. 2022. https:\/\/carers.net.nz\/state-caring-report\/. Accessed 31 Mar 2025."},{"issue":"10","key":"1486_CR68","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.jval.2020.05.017","volume":"23","author":"BM Pennington","year":"2020","unstructured":"Pennington BM. Inclusion of carer health-related quality of life in National Institute for Health and Care Excellence appraisals. Value Health. 2020;23(10):1349\u201357. https:\/\/doi.org\/10.1016\/j.jval.2020.05.017.","journal-title":"Value Health."},{"key":"1486_CR69","unstructured":"Daly C, Anwer S, Welton N, Dias S, Ades A. Meta-analysis of event outcomes: guideline methodology document 3. London, UK: NICE Guidelines Technical Support Unit; 2021. http:\/\/www.bristol.ac.uk\/population-health-sciences\/centres\/cresyda\/mpes\/nice\/guideline-methodology-documents-gmds\/."},{"issue":"16","key":"1486_CR70","doi-asserted-by":"publisher","first-page":"e1546","DOI":"10.1212\/WNL.0000000000012700","volume":"97","author":"SL Hauser","year":"2021","unstructured":"Hauser SL, Kappos L, Montalban X, Craveiro L, Chognot C, Hughes R, et al. Safety of ocrelizumab in patients with relapsing and primary progressive multiple sclerosis. Neurology. 2021;97(16):e1546\u201359. https:\/\/doi.org\/10.1212\/WNL.0000000000012700.","journal-title":"Neurology"},{"key":"1486_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013247.pub2","author":"M Lin","year":"2022","unstructured":"Lin M, Zhang J, Zhang Y, Luo J, Shi S. Ocrelizumab for multiple sclerosis. Cochrane Database Syst Rev. 2022. https:\/\/doi.org\/10.1002\/14651858.CD013247.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1486_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.863105","volume":"13","author":"MS Weber","year":"2022","unstructured":"Weber MS, Buttmann M, Meuth SG, Dirks P, Muros-Le Rouzic E, Eggebrecht JC, et al. Safety, adherence and persistence in a real-world cohort of German MS patients newly treated with ocrelizumab: first insights from the CONFIDENCE study. Front Neurol. 2022;13: 863105. https:\/\/doi.org\/10.3389\/fneur.2022.863105.","journal-title":"Front Neurol"},{"key":"1486_CR73","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3389\/fneur.2017.00577","volume":"8","author":"AM Weideman","year":"2017","unstructured":"Weideman AM, Tapia-Maltos MA, Johnson K, Greenwood M, Bielekova B. Meta-analysis of the age-dependent efficacy of multiple sclerosis treatments. Front Neurol. 2017;8:577. https:\/\/doi.org\/10.3389\/fneur.2017.00577.","journal-title":"Front Neurol"},{"issue":"4","key":"1486_CR74","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/ana.25313","volume":"84","author":"JS Wolinsky","year":"2018","unstructured":"Wolinsky JS, Montalban X, Hauser SL, Giovannoni G, Vermersch P, Bernasconi C, et al. Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial. Ann Neurol. 2018;84(4):527\u201336. https:\/\/doi.org\/10.1002\/ana.25313.","journal-title":"Ann Neurol"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01486-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01486-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01486-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T14:10:27Z","timestamp":1757167827000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01486-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,7]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1486"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01486-z","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,7]]},"assertion":[{"value":"18 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by a grant from Roche Products (New Zealand) Ltd to Multiple Sclerosis New Zealand (MSNZ). Roche NZ reviewed an early draft of the manuscript but neither MSNZ nor Roche had any role in the analysis or interpretation of results or the decision to submit the manuscript for publication. CS is employed as a health economist by F. Hoffmann-La Roche Ltd (Roche) and owns shares in the company. None of the other authors have any relevant financial interest. RM is an Editorial Board Member of PharmacoEconomics. He was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Open Access funding enabled and organized by CAUL and its Member Institutions. RM was funded by a grant from Roche Products (NZ) Ltd to Multiple Sclerosis NZ. He has received conference support from Roche Products (NZ) Ltd. CS is an employee of Roche Singapore Pte and was previously an employee of Pharmac. JC has received funding from Multiple Sclerosis Australia. JM has received honoraria from Roche Products (NZ) Ltd.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Model development by RM and CS; review of cost data by JC; analyses by RM and CS; review of clinical information by JM; manuscript development and final approval by all authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"The Markov model can be obtained from the lead author on request","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}